249 related articles for article (PubMed ID: 33798900)
1. Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.
Epaillard N; Benitez JC; Gorria T; Fabre E; Riudavets M; Reyes R; Planchard D; Oudard S; Viñolas N; Reguart N; Besse B; Mezquita L; Auclin E
Lung Cancer; 2021 May; 155():114-119. PubMed ID: 33798900
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
Wei Q; Deng T; Wu J; Zeng H; Qi C; Tan S; Zhang Y; Huang Q; Pu X; Xu W; Li W; Tian P; Li Y
BMC Cancer; 2024 Mar; 24(1):393. PubMed ID: 38549044
[TBL] [Abstract][Full Text] [Related]
3. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; Dingemans AM; Planchard D; Cozic N; Cassard L; Lopes G; Chaput N; Arbour K; Besse B
Eur J Cancer; 2021 Jul; 151():211-220. PubMed ID: 34022698
[TBL] [Abstract][Full Text] [Related]
4. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study.
Nishimura T; Ichihara E; Yokoyama T; Inoue K; Tamura T; Sato K; Oda N; Kano H; Kishino D; Kawai H; Inoue M; Ochi N; Fujimoto N; Ichikawa H; Ando C; Hotta K; Maeda Y; Kiura K
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551668
[TBL] [Abstract][Full Text] [Related]
6. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
[TBL] [Abstract][Full Text] [Related]
7. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
Rich P; Mitchell RB; Schaefer E; Walker PR; Dubay JW; Boyd J; Oubre D; Page R; Khalil M; Sinha S; Boniol S; Halawani H; Santos ES; Brenner W; Orsini JM; Pauli E; Goldberg J; Veatch A; Haut M; Ghabach B; Bidyasar S; Quejada M; Khan W; Huang K; Traylor L; Akerley W
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706885
[TBL] [Abstract][Full Text] [Related]
8. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Rousseau A; Tagliamento M; Auclin E; Aldea M; Frelaut M; Levy A; Benitez JC; Naltet C; Lavaud P; Botticella A; Grecea M; Chaput N; Barlesi F; Planchard D; Besse B
Eur J Cancer; 2023 Mar; 182():107-114. PubMed ID: 36758475
[TBL] [Abstract][Full Text] [Related]
10. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of Prognostic Factors and Clinical Characteristics for Patients with Limited Stage Small Cell Lung Cancer with Pleural Effusion].
Xu K; Wang Y; Qi J; Zhao L; Wang P
Zhongguo Fei Ai Za Zhi; 2018 Jan; 21(1):16-23. PubMed ID: 29357968
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
[TBL] [Abstract][Full Text] [Related]
14. Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment.
Wang TF; Chu SC; Lee JJ; Yang GG; Huang WH; Chang ET; Low T; Wu YF; Kao RH; Lin CB
Asia Pac J Clin Oncol; 2017 Aug; 13(4):304-313. PubMed ID: 28124437
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis.
Yoshimura A; Yamada T; Tsuji T; Hamashima R; Shiotsu S; Yuba T; Takumi C; Uchino J; Hiraoka N; Takayama K
Thorac Cancer; 2019 Mar; 10(3):557-563. PubMed ID: 30672656
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of minimal pleural effusion in non-small-cell lung cancer.
Ryu JS; Ryu HJ; Lee SN; Memon A; Lee SK; Nam HS; Kim HJ; Lee KH; Cho JH; Hwang SS
J Clin Oncol; 2014 Mar; 32(9):960-7. PubMed ID: 24550423
[TBL] [Abstract][Full Text] [Related]
17. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Botticelli A; Cirillo A; Scagnoli S; Cerbelli B; Strigari L; Cortellini A; Pizzuti L; Vici P; De Galitiis F; Di Pietro FR; Cerbelli E; Ghidini M; D'Amati G; Della Rocca C; Mezi S; Gelibter A; Giusti R; Cortesi E; Ascierto PA; Nuti M; Marchetti P
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32353934
[TBL] [Abstract][Full Text] [Related]
18. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study.
Kawachi H; Tamiya M; Taniguchi Y; Yokoyama T; Yokoe S; Oya Y; Imaji M; Okabe F; Kanazu M; Sakata Y; Uematsu S; Tanaka S; Arai D; Saito G; Kobe H; Miyauchi E; Okada A; Hara S; Kumagai T
JTO Clin Res Rep; 2022 Jul; 3(7):100355. PubMed ID: 35769388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
